Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review

Critical Reviews in Oncology/Hematology

Volumn 87, Issue 1, 2013, Pages 1-11

  Perlikos, Fotis ^a   Harrington, Kevin J ^b,c   Syrigos, Konstantinos N ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Invasion; Lung cancer; Metastasis

Indexed keywords

ANGIOGENESIS; APOPTOSIS; BASEMENT MEMBRANE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER STAGING; CANCER THERAPY; CELL ADHESION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CELL TRANSPORT; DEGRADATION; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE; GENOMIC INSTABILITY; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; REVIEW; TUMOR CELL; TUMOR INVASION;

ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84878549763     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.12.007     Document Type: Review

References (180)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer Journal of Clinicians 2009, 59:225-249.
2. Youlden D.R., Cramb S.M., Baade P.D. The international epidemiology of lung cancer: geographical distribution and secular trends. Journal of Thoracic Oncology 2008, 3:819-831.
3. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nature Reviews Cancer 2006, 6:449-458.
4. Leber M.F., Efferth T. Molecular principles of cancer invasion and metastasis. International Journal of Oncology 2009, 34:881-895.
5. Tarin D. Comparisons of metastases in different organs: biological and clinical implications. Clinical Cancer Research 2008, 14(7):1923-1925.
6. Liu J., Johnston M.R. Experimental animal models for studying lung cancer. Lung cancer metastasis 2009, Springer Science, New York. Keshamouni, Arenberg, Kalekerian (Eds.).
7. Chiang A.C., Massague J. Molecular basis of metastasis. New England Journal of Medicine 2008, 359:2814-2823.
8. Sykes S.M., Mellert H.S., Holbert M.A., et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Molecular Cell 2006, 24:841-851.
9. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
10. Heinrich E.L., Walser T.C., Krysan K., et al. The inflammatory tumor microenvironment epithelial mesenchymal transition and lung carcinogenesis. Cancer Microenvironment 2012, 5:5-18.
11. Kim V., Rogers T.J., Criner G.J. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proceedings of American Thoracic Society 2008, 5:478-485.
12. Wills B.C., Borok Z. TGF-beta-induced EMT: mechanisms and implication for fibrotic lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology 2007, 293:L525-L534.
13. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nature Reviews Cancer 2003, 3:895-902.
14. Lobo N.A., Shimono Y., Qian D., et al. The biology of cancer stem cells. Annual Review of Cell and Developmental Biology 2007, 23:675-699.
15. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annual Review of Medicine 2007, 58:267-284.
16. Hermann R.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
17. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Research 1996, 56:370-376.
18. Kim C.F., Jackson E.L., Woolfenden A.E., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
19. Eramo A., Lotti F., Sette G., et al. Identification and expansion of the tumorgenic lung cancer stem cell population. Cell Death and Differentiation 2008, 15:504-514.
20. Sullivan J.P., Minna J.D., Shay J.W. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer and Metastasis Reviews 2010, 29:61-72.
21. Michor F., Hughes T.P., Iwasa Y., et al. Dynamics of chronic myeloid leukemia. Nature 2005, 435(7046):1267-1270.
22. Kleer C.G., Cao Q., Varambally S., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of National Academy of Sciences United States of America 2003, 100:11606-11611.
23. Berezovska O.P., Glinskii A.B., Yang Z., et al. Essential role for activation of the Polycomb (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006, 5:1886-1901.
24. Topczewska J.M., Postovit L.M., Margaryan NV, et al. Embryonic and tumorgenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nature Medicine 2006, 12:925-932.
25. Ho M.M., Ng A.V., Lam S., et al. Side population in human lung cancer cell lines and tumors are enriched with stem-like cancer cells. Cancer Research 2007, 67:4827-4833.
26. Klein CA, Blankenstein T.J., Shmidt-Kittler O., et al. Genetic heterogeneity of single disseminated tumor cells in minimal residual cancer. Lancet 2002, 360:683-689.
27. Schmidt-Kittler O., Ragg T., Daskalakis A., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proceedings of National Academy of Sciences United States of America 2003, 100:7737-7742.
28. Yan J., Mani S.A., Donaher J.L., et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology 2008, 10:295-305.
29. Thiery J.P. Epithelial-mesenchymal transitions in tumor progression. Nature Reviews Cancer 2002, 2:442-454.
30. Wu Y., Liu H.B., Ding M., et al. The impact of E-cadherin on non-small cell lung cancer survival: a meta-analysis. Molecular Biology Reports 2012, [Epub ahead of print].
31. Ray R.M., Jablons D.M. Hallmarks of metastasis. Lung cancer metastasis 2009, Springer Science, New York. Keshamouni, Arenberg, Kalekerian (Eds.).
32. Yilmaz M., Christofori G. Mechanisms of motility in metastasizing cells. Molecular Cancer Research 2010, 8:629-642.
33. Savary K., Termen S., Thuault S., et al. Epithelial-mesenchymal transition as a mechanism of metastasis. Lung cancer metastasis 2009, Springer Science, New York. Keshamouni, Arenberg, Kalekerian (Eds.).
34. Tian M., Neil J.R., Schiemann W.P. Transforming growth factor-β and the hallmarks of cancer. Cellular Signalling 2011, 23:951-962.
35. Shih J.Y., Yang P.C. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011, 32:1299-1304.
36. Chuang P.T., McMahon A.P. Branching morphogenesis of the lung: new molecular insights into an old problem. Trends in Cell Biology 2003, 13:86-91.
37. Soini Y. Tight junctions in lung cancer and lung metastasis: a review. International Journal of Clinical and Experimental Pathology 2012, 5:126-136.
38. Christofori G. New signals from the invasive front. Nature 2006, 441:444-450.
39. Jechlinger M., Grunert S., Tamir J.M., et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003, 22:7155-7169.
40. Xiao D., He J. Epithelial mesenchymal transition and lung cancer. Journal of Thoracic Disorder 2010, 2:154-159.
41. Hofmeister V., Schrama D., Becker J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunology, Immunotherapy 2008, 57:1-17.
42. Morra L., Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Archiv 2011, 459:465-475.
43. Soltemann A., Tischler V., Abrogast S., et al. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clinical Cancer Research 2008, 14:7430-7437.
44. De Wever O., Mareel M. Role of tissue stroma in cancer cell invasion. Journal of Pathology 2003, 200:429-477.
45. Giatromanolaki A., Sivridis E., Koukourakis M.I. The pathology of tumor stromatogenesis. Cancer Biology and Therapy 2007, 6:6.
46. De Wever O., Demetter P., Mareel M., et al. Stromal myofibroblasts are drivers of invasive cancer growth. International Journal of Cancer 2008, 123:2229-2238.
47. Edme N. Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MARK pathways. Journal of Cell Science 2002, 115:2591-2601.
48. Jenndahl L.E., Isakson P. Baeckström D. c-erbB2-induced epithelial-mesenchymal transition in mammary epithelial cells is suppressed by cell-cell contact and initiated prior to E-cadherin downregulation. International Journal of Oncology 2005, 27:439-448.
49. Mazieres J., He B., You L., et al. Wnt signaling in lung cancer. Cancer Letters 2005, 222:1-10.
50. Liu H., Gu D., Xie J. Clinical implications of hedgehog signaling pathway inhibitors. Chinese Journal of Cancer 2011, 30:13-26.
51. Eccles S.A., Welsh D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
52. Zeisberg E.M., Potenta S., Xie L., et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Research 2007, 67:10123-10128.
53. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transition during cancer progression. Cancer Science 2007, 98:1512-1520.
54. Peinado H., Olmeda D., Cano A., Snail Zeb and bHLH factors in tumor progression: an alliance against the epithelial phenotype?. Nature Reviews Cancer 2007, 7:415-428.
55. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current Opinion in Cell Biology 2005, 17:548-558.
56. Bailey J.M., Singh P.K., Hollingsworth M.A. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog Notch, and bone morphogenetic proteins. Journal of Cellular Biochemistry 2007, 102:829-839.
57. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
58. Higgins D.F., Kimura K., Bernhardt W.M., et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. Journal of Clinical Investigation 2007, 27:157-169.
59. Yang M.H., Wu M.Z., Chiou Sh, et al. Direct regulation of TWIST by HIF-1alpha promotes metastases. Nature Cell Biology 2008, 10:295-305.
60. Jeon H.S., Jen J. TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. Journal of Thoracic Oncology 2010, 5. 417-417.
61. Toonkel R.L., Borczuk A.C., Powell C.A. TGF-β signaling pathway in lung adenocarcinoma invasion. Journal of Thoracic Oncology 2010, 5:153-157.
62. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes and Development 2005, 19:2783-2810.
63. Moustakas A., Heldin C.H. Non-Smad TGF-β signals. Journal of Cellular Science 2005, 118:3573-3584.
64. Valcourt U., Kowanetz M., Niimi H., et al. TGF-β and the Smad signaling pathway support transcriptomic reprogramming during epithelial mesenchymal cell transition. Molecular Biology of the Cell 2005, 16:1987-2002.
65. Kowanetz M., Valcourt U., Bergstrom R., et al. Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphologic protein. Molecular and Cellular Biology 2004, 24:4241-4254.
66. He L., Hannon G.J. MicroRNAs: small RNAs with big role in gene regulation. Nature Reviews Genetics 2004, 5. 544-531.
67. Park S.M., Gaur A.B., Lengyel, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes and Development 2008, 52:189-196.
68. Gregory P.A., Bert A.G., Paterson E.L., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology 2008, 10:593-601.
69. Crawford M., Brawner E., Batte K., et al. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochemical and Biophysical Research Communications 2008, 373:607-612.
70. Oglesby I.K., McElvaney N.G., Greene C.M. MicroRNAs in inflammatory lung disease-master regulators or target practice?. Respiratory Research 2010, 11:148.
71. Baas A.F., Kuipers J., van der Wel N.N., et al. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004, 116:457-466.
72. Marcus A.I., Zhou W. LKB1 regulated pathways in lung cancer invasion and metastasis. Journal of Thoracic Oncology 2010, 5:1883-1886.
73. Thodeti C.K., Ghosh K. Mechanisms of tumor cell migration and invasion in lung cancer metastasis. Lung cancer metastasis 2009, Springer Science, New York. Keshamouni, Arenberg, Kalekerian (Eds.).
74. Ingber D.E. Cellular mechanotransduction: putting all the pieces together again. FASEB Journal 2006, 20:811-827.
75. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
76. Lele T.P., Thodeti C.K., Ingber D.E. Force meets chemistry: analysis of mechanochemical conversion in focal adhesions using fluorescence recovery after photobleaching. Journal of Cellular Biochemistry 2006, 97:1175-1183.
77. Parker K.K., Ingber D.E. Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering. Philosophical Transaction of Royal Society of London B Biological Science 2007, 362:1267-1279.
78. Chen F.A., et al. Clones of tumor cells derived from a single primary human lung tumor revealed different patterns of beta 1 integrin expression. Cell Adhesion Communications 1994, 2:345-357.
79. Gavert N., Conacci-Sorrell M., Gast D., et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. Journal of Cell Biology 2005, 168:633-642.
80. Thies A., Schchner M., Moll I., et al. Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. European Journal of Cancer 2002, 38:1708-1716.
81. Weber G.F. Molecular mechanisms of metastasis. Cancer Letters 2008, 270:181-190.
82. Hall A., Nobes C.D. Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Philosophical Transaction of Royal Society of London B Biological Science 2000, 355:965-970.
83. Ridley A.J., Paterson H.F., Johnston C.L., et al. The small GTP-binding protein Rac regulates growth factor-induced membrane ruffling. Cell 1992, 70:401-410.
84. Bosco E.E., Mulloy J.C., Zheng Y. Rac1 GTPase: a "Rac" of all trades. Cellular and Molecular Life Sciences 2009, 66:370-374.
85. Keshamouni V.G., et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epethelial-mesenchymal transition reveals a migratory/invasive phenotype. Journal of Proteasome Research 2006, 5:1143-1154.
86. Wang W., Eddy R., Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nature Reviews Cancer 2007, 7:429-440.
87. Yamaguchi H., Lorenz M., Kempiak S., et al. Molecolar mechanisms of invadopodiom formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. Current Opinion in Cell Biology 2005, 168:583-595.
88. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002, 2:161-174.
89. Noel A., Jost M., Maquoi Matrix metalloproteinases at cancer tumor-host interface. Seminars in Cell and Developmental Biology 2008, 19:52-60.
90. Rydlova M., et al. Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Research 2008, 28:1389-1397.
91. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer 2011, 128:2527-2535.
92. Kajita M., et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. Journal of Cell Biology 2001, 153:893-904.
93. Sternlich M.D., et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
94. Sauter W., et al. Matrix metalloproteinase 1 (MMP1) is associated with early onset lung cancer. Cancer Epidemiology, Biomarkers and Prevention 2008, 17:1127-1135.
95. Chen J.H., et al. Gasous nitrogen oxide promotes human lung cancer cell line A549 migration, invasion and metastasis via iNOS-mediated MMP-2 production. Toxicological Sciences 2008, 106:364-375.
96. Wolf K., Wu Y.I., Liu Y., et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nature Cell Biology 2007, 9:893-904.
97. Wolf k, Mazo I., Leung H., et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. Journal of Cell Biollogy 2003, 160:267-277.
98. Sanz-Moreno V., Gadea G., Ahn J., et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
99. Burrige K., Wnnerberg K. Rho and Rac take center stage. Cell 2004, 116:167-179.
100. Pankova K., Rosel D., Novotny M., et al. The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells. Cellular and Molecular Life Sciences 2010, 67:63-71.
101. Sahai E., Marshall C.J. Rho-GTPases and cancer. Nature Reviews Cancer 2002, 2:133-142.
102. Wang H.R., Ogunjimi A.A., Zhang Y., et al. Degradation of RhoA by Smurf1 ubiquitin ligase. Methods in Enzymology 2006, 406:437-447.
103. Bates R.C., Edwards N.S., Yates J.D. Spheroids and cell survival. Critical Reviews in Oncology/Hematology 2000, 36:61-74.
104. Friedl P., Wolf K. Tumor-cell invasion and migration: diversity and escape mechanisms. Nature Reviews Cancer 2003, 3:362-374.
105. Nikiforov M.A., Hagen K., Ossovskaya V.S., et al. p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996, 13:1709-1719.
106. Nikiforov M.A., Kwek S.S., Mehta R., et al. Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. Oncogene 1997, 15:3007-3012.
107. Martin S.S., Vuori K. Regulation of Bcl-2 proteins during anoikis and amorphosis. Molecular Cell Research 2004, 1692:145-157.
108. Frisch S.M., Rusoslahti E. Integrins and anoikis. Current Opinion in Cell Biology 1997, 9:701-706.
109. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology 1994, 4:619-626.
110. Frisch S.M., Vuori K., Ruoslahti E., et al. Control of adhesion-dependent cell survival by focal adhesion kinase. Journal of Cell Biology 1996, 134:793-799.
111. Attwell S., Roskelley C., Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000, 19:3811-3815.
112. McLean G.W., Carragher N.O., Avizienyte E. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nature Reviews Cancer 2005, 5:505-515.
113. Onder T.T., Gupta P.B., Mani S.A., et al. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research 2008, 68:3645-3654.
114. Smit M.A., Geiger T.R., Song J.Y., et al. A twist-snail axis critical for TrkB-induced EMT-like transformation, anoikis, resistance and metastasis. Molecular and Cellular Biology 2009, 29:3722-3737.
115. Douma S., van Laar T., Zevenhoven J., et al. Suppression of anoikis and induced of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
116. Geiger T.R., Peeper D.S. Critical role for TrkB kinase function in anoikis suppression, tumorgenesis and metastasis. Cancer Research 2007, 67:6221-6229.
117. Yang L., Huang J., Ren X., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloeid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
118. Chicurel M.E., Chen C.S., Ingber DE Cellular control lies in the balance of forces. Current Opinion in Cell Biology 1998, 10:232-239.
119. White S.R., Williams P., Wojcik K.R., et al. Initiation of apoptosis by actin cytoskeletal derangement in human airway epithelial cells. American Journal of Respiratory Cell and Molecular Biology 2001, 24:282-294.
120. Choquet D., Felsenfeld D.P., Sheetz M.P. Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. Cell 1997, 88:39-48.
121. Paul C., Manero F., Gonin S., et al. Hsp27 as a negative regulator of cytochrome c release. Molecular and Cellular Biology 2002, 22:816-834.
122. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., et al. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Molecular and Cellular Biology 1997, 18:3509-3517.
123. Vermeulen P.B., van Golen K.L., Dirix L.Y. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer 2010, 116:2748-2754.
124. Janic B., Arbab A.S. The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. Scientific World Journal 2010, 10:1088-1099.
125. Keeley E.C., Mehrad B., Strieter R.M. CXC chemokines in cancer angiogenesis and metastases. Advanced Cancer Research 2010, 106:91-111.
126. Hall K., Ran S. Regulation of tumor angiogenesis by the local environment. Frontiers in Bioscience 2010, 15:195-212.
127. Arenberg D.A. Angiogenesis and angiogenetic diversity in lung cancer metastasis. Lung cancer metastasis 2009, Springer Science, New York. Keshamouni, Arenberg, Kalekerian (Eds.).
128. Bergers G., Benjamin L.E. Tumorgenesis and the angiogenetic switch. Nature Reviews Cancer 2003, 3:401-410.
129. Harris A.I. Hypoxia - key regulatory factor in tumour growth. Nature Reviews Cancer 2002, 2:38-47.
130. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011, 117:3889-3899.
131. McClelland M.R., Carskadon S.L., Zhao L., et al. Diversity of angiogenetic phenotype in non-small cell lung cancer. American Journal of Respiratory Cell and Molecular Biology 2007, 37:343-350.
132. Brantley D.M., Cheng N., Thompsom Ej, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21:7011-7026.
133. Fukumura D., Xavier R., Sugiura T., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
134. White E.S., Strom S.R.B., Wys N.L., et al. Non-small cell lung cancer cells induce monocykes to increase expression of angiogenetic activity. Journal of Immunology 2001, 166:319-331. 7549-755526.
135. Sullivan R., Graham C.M. Hypoxia-driven selection of the metastatic phenotype. Cancer and Metastasis Reviews 2007.
136. Graves E.E., Maity A.M., Le Q.T. The tumor microenvironment in non-small cell lung cancer. Seminars in Radiation Oncology 2010, 20:153-163.
137. Potenta S., Zeisberg E., Kalluri R. The role of endothelial-to-mesenchymal transition in cancer progression. British Journal of Cancer 2008, 99:1375-1379.
138. Matsumura T., Wolf K., Petzelbauer P. Endothelial cell tube formation depends on cadherin 5 and CD31 interactions with filamentous actin. Journal of Immunology 1997, 158:3408-3416.
139. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB Journal 2004, 18:338-340.
140. Sadler A.B., Gray R., Brahmer J., et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. Journal of Clinical Oncology 2005, 23:16s. 2s (abstr. 4).
141. Stacker S.A., Achen M.G., Jussila L., et al. Lymphangiogenesis and cancer metastasis. Nature Reviews Cancer 2002, 2:573-583.
142. El-Chemaly S., Levine S.J., Moss J. Lymphatics in lung disease. Annals of the New York Academy of Sciences 2008, 1131:195-202.
143. Ristimaki A., Narko K., Enholm B. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. Journal of Biological Chemistry 1998, 273:8413-8418.
144. OlssonAK, et al. VEGF receptor signaling - in control of vascular function. Nature Reviews in Molecular Cell Biology 2006, 7:359-371.
145. Kojima H., Shijubo N., Yamada G. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 2005, 92:1231-1239.
146. Lin E.Y., Pollard J.W. Tumor-associated macrophages press the angiogenetic switch in breast cancer. Cancer Research 2007, 67:5064-5066.
147. Padera T.P., Kadambi A., di Tomaso E., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
148. Cao Y. Opinion: emerging mechanisms of tumor lymphangiogenesis and lymphatic metastasis. Nature Reviews Cancer 2005, 5:735-743.
149. Sahai E. Illuminating the metastatic process. Nature Reviews Cancer 2007, 7:737-749.
150. Siveen K.S., Kuttan G. Role of macrophages in tumour progression. Immunology Letters 2009, 123:97-102.
151. Zlotnik A. Chemokines in neoplastic progression. Seminar in Cancer Biology 2004, 14:181-185.
152. Bockhorn M., Jain R.K., Munn L.L. Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed?. Lancet Oncology 2007, 8:444-448.
153. Wychoff J.B., Jones J.G., Condeelis J.S., et al. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Research 2000, 60:2504-2511.
154. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters 2007, 253:180-204.
155. Pardoll D. Does the immune system see tumors as foreign or self?. Annual Review of Immunology 2003, 21:807-839.
156. O'Flaherty J.D., Gray S., Richard D., et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012, 76:19-25.
157. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews Cancer 2008, 8:329-340.
158. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nature Medicine 2006, 12:895-904.
159. Morgan T.M., Lange P.H., Porter M.P., et al. Disseminated tumor cells in prostate cancer patients after radical protatectomy and wighout evidence of disease predicts biochemical recurrence. Clinical Cancer Research 2009, 15:677-683.
160. Hou J.M., Krebs M., Ward T., et al. Circulating tumor cells as a window on metastais biology in lung cancer. American Journal of Pathology 2011, 178:989-996.
161. Hou J.M., Greystoke A., Lancashire L., et al. Evaluation of circulating tumor cells and serological death biomarkers in small cell lung cancer patients undergoing chemotherapy. American Journal of Pathology 2009, 175:808-816.
162. Sequist L.V., Nagrath S., Toner M., et al. The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. Journal of Thoracic Oncology 2009, 4:281-283.
163. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. New England Journal of Medicine 2008, 359:366-377.
164. Hofman V., Bonnetaud C., Ilie M.I., et al. Preoperative circulating tumor detection using the isolation by size epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clinical Cancer Research 2011, 17:827-835.
165. Kopp H.G., Placke T., Salih H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Research 2009, 10:355-362.
166. Erpenbeck L., Nieswandt B., Schon M., et al. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. Journal of Investigative Dermatology 2010, 130:576-586.
167. Amirkhosravi A., Mousa S.A., Amaya M., et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thrombosis and Haemostasis 2003, 90:549-554.
168. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
169. Zeelenberg L.S., Ruuls-van Stalle L., Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Research 2003, 63:3833-3839.
170. Brown D.M., Ruoslahti E., Metadherin A cell surface protein in breast cancer that mediates lung metastasis. Cancer Cell 2005, 5:365-374.
171. Mishra A., Shiozawa Y., Pienta K.J., et al. Homing of cancer cells to the bone. Cancer Microenvironment 2011, 4:221-235.
172. Wang H., Fu W., Im J.H., et al. Tumor cell alpha3beta1 integrin and vascular lamini-5 mediate pulmonary arrest and metastasis. Journal of Cell Biology 2004, 164:935-941.
173. Witz I.P. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Research 2008, 27:19-30.
174. Im J.H., Fu W., Wang H., et al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Research 2004, 64:8613-8619.
175. Ji H., Ramsey M.R., Hayes D.N., et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448:807-810.
176. Galaup A., Cazes A., Le Jan S., et al. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proceedings of National Academy Science United States of America 2006, 103:18721-18726.
177. Morris V.L., Schmidt E.E., MacDonald I.C., et al. Sequential steps in hematogenous metastasis of cancer cells studied by in vivo videomicroscopy. Invasion and Metastasis 1997, 17:281-296.
178. Naumov G.N., MacDonald I.C., Weinmeister P.M., et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Research 2002, 62:2162-2168.
179. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer 2002, 2:563-572.
180. Yu Q., Toole B.P., Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. Journal of Experimental Medicine 1997, 1985-1996.